Does tight control of systemic factors help in the management ofdiabetic retinopathy?

Indian Journal of Ophthalmology

Volumn 64, Issue 1, 2016, Pages 62-68

  Rajalakshmi, Ramachandran ^a   Prathiba, Vijayaraghavan ^a   Mohan, Viswanathan ^b  

^a Dr Mohan's Diabetes Specialities Centre   (India)

^b MADRAS DIABETES RESEARCH FOUNDATION   (India)

Author keywords

Control of systemic factors; diabetic retinopathy; glycemic control

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SITAGLIPTIN;

BLOOD PRESSURE; DIABETES MELLITUS; DIABETIC RETINOPATHY; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; VISUAL DISORDER;

BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS; DIABETIC RETINOPATHY; GLYCATED HEMOGLOBIN A; GLYCEMIC INDEX; HUMANS; HYPOGLYCEMIC AGENTS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SITAGLIPTIN PHOSPHATE; THIAZOLIDINEDIONES; VISION DISORDERS;

EID: 84961774447     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.178146     Document Type: Conference Paper

References (69)

1. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-64.
2. World Health Organization. Global Initiative for the Elimination of Avoidable Blindness. WHO/PBL/97.61 Rev 2; 2006. Available from: http://www.who.int/blindness/Vision2020-report.pdf. [Last accessed on 2016 Jan 05].
3. Pradeepa R, Anitha B, Mohan V, Ganesan A, Rema M. Risk factors for diabetic retinopathy in a South Indian type 2 diabetic population-The Chennai urban rural epidemiology study (CURES) eye study 4. Diabet Med 2008;25:536-42.
4. Raman R, Rani PK, Reddi Rachepalle S, Gnanamoorthy P, Uthra S, Kumaramanickavel G, et al. Prevalence of diabetic retinopathy in India: Sankara Nethralaya diabetic retinopathy epidemiology and molecular genetics study report 2. Ophthalmology 2009;116:311-8.
5. Aiello LP, Cahill MT, Wong JS. Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 2001;132:760-76.
6. Rodriguez-Fontal M, Kerrison JB, Alfaro DV, Jablon EP. Metabolic control and diabetic retinopathy. Curr Diabetes Rev 2009;5:3-7.
7. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
9. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968-83.
10. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000;342:381-9.
11. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23 Suppl 2:B21-9.
12. ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-44.
13. Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: The action to control cardiovascular risk in diabetes (ACCORD) eye study. Ophthalmology 2014;121:2443-51.
14. Beulens JW, Patel A, Vingerling JR, Cruickshank JK, Hughes AD, Stanton A, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: A randomised controlled trial. Diabetologia 2009;52:2027-36.
15. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
16. White NH, Waltman SR, Krupin T, Santiago JV. Reversal of abnormalities in ocular fluorophotometry in insulin-dependent diabetes after five to nine months of improved metabolic control. Diabetes 1982;31:80-5.
17. Early worsening of diabetic retinopathy in the diabetes control and complications trial. Arch Ophthalmol 1998;116:874-86.
18. Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 1998;82:725-30.
19. Silva PS, Cavallerano JD, Sun JK, Aiello LM, Aiello LP. Effect of systemic medications on onset and progression of diabetic retinopathy. Nat Rev Endocrinol 2010;6:494-508.
20. Avogaro A, Fadini GP. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care 2014;37:2884-94.
21. Ryan EH Jr., Han DP, Ramsay RC, Cantrill HL, Bennett SR, Dev S, et al. Diabetic macular edema associated with glitazone use. Retina 2006;26:562-70.
22. Mohan V, Seedat YK, Pradeepa R. The rising burden of diabetes and hypertension in Southeast Asian and African regions: Need for effective strategies for prevention and control in primary health care settings. Int J Hypertens 2013;2013:409083.
23. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.
24. Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: Prospective cohort study. BMJ 2008;337:a918.
25. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB controlled trial of lisinopril in insulin-dependent diabetes mellitus. Lancet 1998;351:28-31.
26. Klein R, Moss SE, Sinaiko AR, Zinman B, Gardiner R, Suissa S, et al. The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus: The renin-angiotensin system study. Ophthalmology 2006;113:2231-6.
27. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51.
28. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: Randomised, placebo-controlled trials. Lancet 2008;372:1394-402.
29. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): A randomised placebo-controlled trial. Lancet 2008;372:1385-93.
30. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20.
31. American Diabetes Association. Microvascular complications and foot care. Diabetes Care 2015;38 Suppl 1:S58-66.
32. Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin epidemiologic study of diabetic retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991;98:1261-5.
33. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early treatment diabetic retinopathy study (ETDRS) report 22. Arch Ophthalmol 1996;114:1079-84.
34. Rema M, Srivastava BK, Anitha B, Deepa R, Mohan V. Association of serum lipids with diabetic retinopathy in urban South Indians-The Chennai urban rural epidemiology study (CURES) eye study-2. Diabet Med 2006;23:1029-36.
35. Das R, Kerr R, Chakravarthy U, Hogg RE. Dyslipidemia and diabetic macular edema: A systematic review and meta-analysis. Ophthalmology 2015;122:1820-7.
36. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 2007;370:1687-97.
37. Suehiro M, Ohkubo K, Kato H, Kido Y, Anzai K, Oshima K, et al. Analyses of serum lipoprotein(a) and the relation to phenotypes and genotypes of apolipoprotein(a) in type 2 diabetic patients with retinopathy. Exp Clin Endocrinol Diabetes 2002;110:319-24.
38. Hu A, Luo Y, Li T, Guo X, Ding X, Zhu X, et al. Low serum apolipoprotein A1/B ratio is associated with proliferative diabetic retinopathy in type 2 diabetes. Graefes Arch Clin Exp Ophthalmol 2012;250:957-62.
39. Manaviat MR, Afkhami M, Shoja MR. Retinopathy and microalbuminuria in type II diabetic patients. BMC Ophthalmol 2004;4:9.
40. Rani PK, Raman R, Gupta A, Pal SS, Kulothungan V, Sharma T. Albuminuria and diabetic retinopathy in type 2 diabetes mellitus Sankara Nethralaya diabetic retinopathy epidemiology and molecular genetic study (SN-DREAMS, report 12). Diabetol Metab Syndr 2011;3:9.
41. Pradeepa R, Anjana RM, Unnikrishnan R, Ganesan A, Mohan V, Rema M. Risk factors for microvascular complications of diabetes among South Indian subjects with type 2 diabetes-The Chennai urban rural epidemiology study (CURES) eye study-5. Diabetes Technol Ther 2010;12:755-61.
42. Roy R, Das MK, Pal BP, Ganesan S, Raman R, Sharma T. The effects of renal transplantation on diabetic retinopathy: Clinical course and visual outcomes. Indian J Ophthalmol 2013;61:552-6.
43. Singh SK, Behre A, Singh MK. Diabetic retinopathy and microalbuminuria in lean type 2 diabetes mellitus. J Assoc Physicians India 2001;49:439-41.
44. Stephenson JM, Fuller JH, Viberti GC, Sjolie AK, Navalesi R. Blood pressure, retinopathy and urinary albumin excretion in IDDM: The EURODIAB IDDM complications study. Diabetologia 1995;38:599-603.
45. Moriya T, Tanaka S, Kawasaki R, Ohashi Y, Akanuma Y, Yamada N, et al. Diabetic retinopathy and microalbuminuria can predict macroalbuminuria and renal function decline in Japanese type 2 diabetic patients: Japan diabetes complications study. Diabetes Care 2013;36:2803-9.
46. Qiao Q, Keinänen-Kiukaanniemi S, Läärä E. The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol 1997;50:153-8.
47. He BB, Xu M, Wei L, Gu YJ, Han JF, Liu YX, et al. Relationship between anemia and chronic complications in Chinese patients with type 2 diabetes mellitus. Arch Iran Med 2015;18:277-83.
48. Ranil PK, Raman R, Rachepalli SR, Pal SS, Kulothungan V, Lakshmipathy P, et al. Anemia and diabetic retinopathy in type 2 diabetes mellitus. J Assoc Physicians India 2010;58:91-4.
49. McGill JB, Bell DS. Anemia and the role of erythropoietin in diabetes. J Diabetes Complications 2006;20:262-72.
50. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early treatment diabetic retinopathy study report #18. Invest Ophthalmol Vis Sci 1998;39:233-52.
51. Jew OM, Peyman M, Chen TC, Visvaraja S. Risk factors for clinically significant macular edema in a multi-ethnics population with type 2 diabetes. Int J Ophthalmol 2012;5:499-504.
52. Li W, Sinclair SH, Xu GT. Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema. Ophthalmic Surg Lasers Imaging 2010;41:18-25.
53. Kramer CK, Rodrigues TC, Canani LH, Gross JL, Azevedo MJ. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: Meta-analysis of observational studies. Diabetes Care 2011;34:1238-44.
54. Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis 2011;218:13-8.
55. Pradeepa R, Surendar J, Indulekha K, Chella S, Anjana RM, Mohan V. Relationship of diabetic retinopathy with coronary artery disease in Asian Indians with type 2 diabetes: The Chennai urban rural epidemiology study (CURES) eye study-3. Diabetes Technol Ther 2015;17:112-8.
56. Alonso N, Traveset A, Rubinat E, Ortega E, Alcubierre N, Sanahuja J, et al. Type 2 diabetes-associated carotid plaque burden is increased in patients with retinopathy compared to those without retinopathy. Cardiovasc Diabetol 2015;14:33.
57. Rema M, Mohan V, Deepa R, Ravikumar R; Chennai urban rural epidemiology study. Association of carotid intima-media thickness and arterial stiffness with diabetic retinopathy: The Chennai urban rural epidemiology study (CURES-2). Diabetes Care 2004;27:1962-7.
58. Bergerhoff K, Clar C, Richter B. Aspirin in diabetic retinopathy. A systematic review. Endocrinol Metab Clin North Am 2002;31:779-93.
59. Samra KA. The eye and visual system in pregnancy, what to expect? An in-depth review. Oman J Ophthalmol 2013;6:87-91.
60. Pescosolido N, Campagna O, Barbato A. Diabetic retinopathy and pregnancy. Int Ophthalmol 2014;34:989-97.
61. Egan AM, McVicker L, Heerey A, Carmody L, Harney F, Dunne FP. Diabetic retinopathy in pregnancy: A population-based study of women with pregestational diabetes. J Diabetes Res 2015;2015:310239.
62. Bhatnagar A, Ghauri AJ, Hope-Ross M, Lip PL. Diabetic retinopathy in pregnancy. Curr Diabetes Rev 2009;5:151-6.
63. Schocket LS, Grunwald JE, Tsang AF, DuPont J. The effect of pregnancy on retinal hemodynamics in diabetic versus nondiabetic mothers. Am J Ophthalmol 1999;128:477-84.
64. Dirani M, Xie J, Fenwick E, Benarous R, Rees G, Wong TY, et al. Are obesity and anthropometry risk factors for diabetic retinopathy? The diabetes management project. Invest Ophthalmol Vis Sci 2011;52:4416-21.
65. R a m a n R , R a n i P K , G n a n a m o o r t h y P, S u d h i r R R , Kumaramanikavel G, Sharma T. Association of obesity with diabetic retinopathy: Sankara Nethralaya diabetic retinopathy epidemiology and molecular genetics study (SN-DREAMS Report no 8). Acta Diabetol 2010;47:209-15.
66. Kaštelan S, Tomic M, Gverovic Antunica A, Ljubic S, Salopek Rabatic J, Karabatic M. Body mass index: A risk factor for retinopathy in type 2 diabetic patients. Mediators Inflamm 2013;2013:436329.
67. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Saito Y. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia 2003;46:1483-8.
68. Katusic D, Tomic M, Jukic T, Kordic R, Sikic J, Vukojevic N, et al. Obesity-A risk factor for diabetic retinopathy in type 2 diabetes? Coll Antropol 2005;29 Suppl 1:47-50.
69. Raum P, Lamparter J, Ponto KA, Peto T, Hoehn R, Schulz A, et al. Prevalence and cardiovascular associations of diabetic retinopathy and maculopathy: Results from the Gutenberg health study. PLoS One 2015;10:e0127188.